Low-profile single and dual vascular access device

Information

  • Patent Grant
  • 11420033
  • Patent Number
    11,420,033
  • Date Filed
    Friday, November 10, 2017
    6 years ago
  • Date Issued
    Tuesday, August 23, 2022
    a year ago
Abstract
A low-profile access port for subcutaneous implantation within a patient is disclosed. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable catheter-bearing needle access to the port without difficulty. In one embodiment, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end, and a receiving cup. The receiving cup is funnel shaped to direct a catheter-bearing needle into the conduit via the inlet port. The conduit is defined by the body and extends from the inlet port to an outlet defined by a stem. A bend in the conduit enables catheter advancement past the bend while preventing needle advancement. A valve/seal assembly is also disposed in the conduit and enables passage of the catheter therethrough while preventing fluid backflow. The body includes radiopaque indicia configured to enable identification of the access port via x-ray imaging.
Description
BRIEF SUMMARY

Briefly summarized, embodiments of the present invention are directed to a low-profile access port for subcutaneous implantation within the body of a patient. The access port includes a receiving cup that provides a relatively large subcutaneous target to enable a catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit pressurized fluid injection through the port while preventing backflow.


In one embodiment, therefore, a low-profile access port comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is concavely shaped to direct a catheter-bearing needle into the conduit via the inlet port. The receiving cup is oriented substantially toward a skin surface when subcutaneously implanted within the patient to ease needle impingement thereon. A valve/seal assembly disposed in the conduit enables passage of the catheter therethrough while preventing fluid backflow.


In another embodiment, a low-profile access port for subcutaneous implantation within the patient is disclosed and comprises a body including a conduit with an inlet port at a proximal end thereof, and a receiving cup. The receiving cup is funnel shaped to direct a catheter-bearing needle into the conduit via the inlet port. The conduit is defined by the body and extends from the inlet port to an outlet defined by a stem. A bend in the conduit enables catheter advancement past the bend while preventing needle advancement. A valve/seal assembly is also disposed in the conduit and enables passage of the catheter therethrough while preventing fluid backflow. The body includes radiopaque indicia configured to enable identification of the access port via x-ray imaging.


In light of the above, embodiments herein are generally directed to a vascular access device, also referred to herein as an access port, for subcutaneous implantation within the body of a patient. The implanted access port is transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.


These and other features of embodiments of the present invention will become more fully apparent from the following description and appended claims, or may be learned by the practice of embodiments of the invention as set forth hereinafter.





BRIEF DESCRIPTION OF THE DRAWINGS

A more particular description of the present disclosure will be rendered by reference to specific embodiments thereof that are illustrated in the appended drawings. It is appreciated that these drawings depict only typical embodiments of the invention and are therefore not to be considered limiting of its scope. Example embodiments of the invention will be described and explained with additional specificity and detail through the use of the accompanying drawings in which:



FIGS. 1A-1E show various views of an access port according to one embodiment;



FIG. 2 is a cross sectional view of the access port of FIGS. 1A-1E;



FIG. 3A-3C are various views of a low-profile access port according to one embodiment;



FIG. 4 is a top view of a low-profile access port according to one embodiment;



FIG. 5 is a perspective view of a low-profile access port according to one embodiment;



FIG. 6 is a perspective view of a low-profile access port according to one embodiment;



FIGS. 7A and 7B are various views of an access port according to one embodiment;



FIGS. 8A and 8B are various views of an access port according to one embodiment;



FIGS. 9A-9G depict various views of a low-profile vascular access device according to one embodiment;



FIG. 10 is an exploded view of the access device of FIGS. 9A-9G;



FIG. 11 is a cross-sectional view of the access device of FIGS. 9A-9G;



FIGS. 12A-12C depict various views of a seal according to one embodiment;



FIGS. 13A-13C depict various views of a valve according to one embodiment;



FIGS. 14A-14D depict various stages of insertion of a catheter into the access device of FIGS. 9A-9G;



FIGS. 15A and 15B depict various views of a guide device for use with the access device of FIGS. 9A-9G according to one embodiment;



FIGS. 16A-16G depict various views of a low-profile vascular access device according to one embodiment;



FIGS. 17A and 17B depict various views of the vascular access port of FIGS. 16A-16G;



FIG. 18 is an exploded view of the vascular access device of FIGS. 16A-16G;



FIG. 19 is a partially transparent view of the vascular access device of FIGS. 16A-16G;



FIG. 20 is a perspective view of a portion of the vascular access device of FIGS. 16A-16G;



FIGS. 21A and 21B are cutaway views of the vascular access device of FIGS. 16A-16G;



FIGS. 22A-22C depict various views of a low-profile vascular access device according to one embodiment;



FIG. 23 is a partially transparent view of the vascular access device of FIGS. 22A-22C;



FIG. 24 is a partially transparent view of a portion of the vascular access port of FIGS. 22A-22C;



FIGS. 25A-25E depict various views of a low-profile vascular access device according to one embodiment;



FIGS. 26A-26D depict various views of a low-profile vascular access device according to one embodiment;



FIG. 27 is a cross-sectional view of a valve/seal configuration according to one embodiment;



FIG. 28 is a cross-sectional view of a valve/seal configuration according to one embodiment;



FIG. 29 is a cross-sectional view of a valve/seal configuration according to one embodiment;



FIG. 30 is a cross-sectional view of a valve/seal configuration according to one embodiment; and



FIG. 31 is a perspective view of a portion of a vascular access device according to one embodiment.





DETAILED DESCRIPTION OF SELECTED EMBODIMENTS

Reference will now be made to figures wherein like structures will be provided with like reference designations. It is understood that the drawings are diagrammatic and schematic representations of exemplary embodiments of the present invention, and are neither limiting nor necessarily drawn to scale.


For clarity it is to be understood that the word “proximal” refers to a direction relatively closer to a clinician using the device to be described herein, while the word “distal” refers to a direction relatively further from the clinician. For example, the end of a catheter placed within the body of a patient is considered a distal end of the catheter, while the catheter end remaining outside the body is a proximal end of the catheter. Also, the words “including,” “has,” and “having,” as used herein, including the claims, shall have the same meaning as the word “comprising.”


Embodiments of the present invention are generally directed to an access port for subcutaneous implantation within the body of a patient. The implanted access port is transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.


In accordance with one embodiment, the access port defines a low profile so as to facilitate ease of placement within the subcutaneous tissue of the patient. Further, the access port is configured to provide a relatively large subcutaneous target to enable the PIV catheter or other suitable catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit the injection of fluids through the access port at a relatively high flow rate, such as about 5 ml per second at a pressure of about 300 psi (also referred to herein as “power injection”). Possible applications for the access port described herein include administration of medicaments and other fluids to the patient, pheresis/apheresis, fluid aspiration, etc.


Reference is first made to made to FIGS. 1A-1E, which show various details of an access port, generally designated at 10, in accordance with one embodiment. As shown, the port 10 includes a body 12 that is defined in the present embodiment by a first portion 12A and a second portion 12B (FIG. 1E). In the present embodiment the port body 12 includes a metal such as titanium, and as such, the second portion 12B is press fit into engagement with the first portion 12A to define the body, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc.


The port body 12 defines in the present embodiment a substantially concavely-shaped receiving cup 14 for receiving and directing a catheter-bearing needle (FIG. 2) to operably connect with the port 10, as described further below. In particular, the substantially concave shape of the receiving cup 14 is configured to direct a catheter-bearing needle (FIG. 2) impinging thereon toward an inlet port 16 that serves as an opening for a conduit 18 defined by the port body 12. The open and shallow nature of the receiving cup 14 together with its substantially upward orientation (i.e., toward the skin surface of the patient), so that it is substantially parallel to the skin surface when subcutaneously implanted under the skin of the patient (i.e., the receiving cup is substantially parallel to the skin surface when the skin is at rest, or undeformed by digital pressure or manipulation), enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin, as seen in FIG. 2. FIG. 2 further shows that the port 10 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the port after implantation.


Palpation features 26 are included with the port body 12 to assist a clinician to locate and/or identify the port 10 via finger palpation after implantation under the skin of the patient. In detail, the palpation features 26 in the present embodiment include a bump 26A disposed near the proximal end of the receiving cup 14 and a ridge 26B disposed above and curving around a distal portion of the receiving cup. FIG. 1B shows that the palpation features extend above the general upper plane defined by the port 10 so as to facilitate palpation of the features by a clinician in order to locate the position and/or orientation of the receiving cup 14. Note that a variety of other sizes, configurations, numbers, etc., of palpation features can be included on the port in addition to what is shown and described herein.


A guide groove 28 is defined on the receiving cup 14 and is longitudinally aligned with the inlet port 16 of the conduit 18. The guide groove 28 is defined as a depression with respect to adjacent portions of the surface of the receiving cup 14 and extends distally along the receiving cup surface from a proximal portion of the receiving cup so as to provide a guide path to guide the distal tip of the catheter-bearing needle toward the inlet port 16 once impingement of the needle into the guide groove is made. This in turn reduces the chance the needle will slide across and off the receiving cup 14 during insertion. Note that these and other similar features, though differing in shape and configuration, can also be included on the other ports disclosed herein.


As best seen in FIG. 1E, the port body 12 further defines the conduit 18 as a pathway into which a transcutaneously inserted catheter can pass so as to place the catheter in fluid communication with the port 10. As shown, the conduit 18 is in communication with the receiving cup 14 via the inlet port 16. A first conduit portion 18A of the conduit 18 distally extends from the inlet port 16 in an angled downward direction from the perspective shown in FIG. 1E to a bend 30, where a second conduit portion 18B of the conduit angles slightly upward and changes direction at a predetermined angle θ1. Note that angle orientation θ1 in one embodiment is about 37 degrees, but can vary from this in other embodiments, including angles less than 37 degrees in one embodiment. The magnitude of angle θ1 depends in one embodiment on various factors, including the size of the catheter and/or needle to be inserted into the port conduit, the size of the conduit itself, etc.


The conduit 18 then extends to and through a cavity 20A defined by a valve housing 20 of the port body. The conduit 18 extends to a distal open end of the stem 24 of the port 10. The conduit 18 is sized so as to enable the catheter 40 (FIG. 2) to pass therethrough, as will be seen.


As mentioned, the valve housing 20 defines a cavity 20A through which the conduit passes and which houses a valve/seal assembly 22. The valve/seal assembly 22 includes a sealing element, or seal 32, which defines a central hole through which the catheter 40 can pass, a first slit valve 34A and a second slit valve 34B. The seal 32 and valves 34A, 34B are sandwiched together in one embodiment and secured in place within the cavity 20A as shown in FIG. 1E. The slits of the slit valves 34A, 34B are rotationally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible.


The seal 32 and valves 34A, 34B of the valve/seal assembly 22 cooperate to enable fluid-tight passage therethrough of the catheter 40 (FIG. 2) while also preventing backflow of fluid through the valve/seal assembly. Indeed, in one embodiment the seals disclosed herein prevent fluid flow around the external portion of the catheter when the catheter is disposed through the seal, while the valves are suitable for preventing fluid flow when no catheter passes through them. As such, when the catheter 40 is not inserted therethrough the valve/seal assembly 22 seals to prevent passage of air or fluid. In the present embodiment, the seal 32 and valves 34A, 34B include silicone, though other suitably compliant materials can be employed.


The port 10 in the present embodiment includes an overmolded portion 36 that covers the port body 12. The overmolded portion 36 includes silicone or other suitably compliant material and surrounds the body 12 as shown so as to provide a relatively soft surface for the port 10 and reduce patient discomfort after port implantation. The overmolded portion 36 includes two predetermined suture locations 38, best seen in FIG. 1C, for suturing the port 10 to patient tissue, though sutures may be passed through other portions of the overmolded portion, if desired. The overmolded portion 36 further defines a relatively flat bottom surface 36A so as to provide a stable surface for the port 10 in its position within the tissue pocket after implantation. In contrast, the port shown in FIG. 3C includes a bottom surface with a slightly rounded profile.



FIG. 2 depicts details regarding the insertion of the catheter 40 disposed on the needle 42, according to one embodiment. After locating the port 10 via through-skin palpation of the palpation features 26, a clinician uses the catheter-bearing needle 42 to pierce a skin surface 44 and insert the needle until a distal tip 42A thereof impinges on a portion of the receiving cup 14, as shown. Note that, because of the orientation of the receiving cup 14 as substantially parallel to the skin surface, the needle 42 can impinge on the receiving cup at an insertion angle θ2 that is relatively steep, which facilitates ease of needle insertion into the body. Indeed, in one embodiment a needle inserted substantially orthogonally through the skin of the patient can impinge the receiving cup of the access port.


The needle 42 is manipulated until the distal tip 42A is received into the guide groove 28, which will enable the distal tip to be guided along the groove to the inlet port 16. The needle 42 is then inserted through the inlet port 16 and into the first portion 18A of the conduit 18 until it is stopped by the bend 30. The needle 42 can then be proximally backed out a small distance, and the catheter 40 advanced over the needle such that the catheter bends and advances past the bend 30 into the second portion 18B of the conduit 18. Catheter advancement continues such that a distal end 40A of the catheter 40 advances into and past the hole of the seal 32 and through both slits of the slit valves 34A, 34B of the valve/seal assembly 40. Once the distal end 40A of the catheter 40 has extended distally past the valve/seal assembly 22, further advancement can cease and fluid transfer through the catheter 40 and port 10 can commence, including infusion and/or aspiration through the stem 24. Once fluid transfer is completed, the catheter 40 can be withdrawn proximally through the valve/seal assembly 22 and the conduit, then withdrawn through the surface 44 of the skin and out of the patient.



FIGS. 3A-3C depict details of an access port 110 according to another embodiment. Note that various similarities exist between the port 10 and the other ports shown and described herein. As such, only selected port aspects are discussed below. As shown, the port 110 includes a body 112 that in turn includes a first body portion 112A and a second body portion 112B, best seen in FIG. 3C. The body 112 in the present embodiment includes a thermoplastic, such as an acetyl resin in the present embodiment. As such, the first and second body portions 112A, 112B are ultrasonically welded to one another to define the body 12, in the present embodiment. As before, a receiving cup 114 is included with the body 112 and is operably connected to a conduit 118 via an inlet port 116. Also, note that a variety of materials can be used to define the port body, receiving cup, conduit, etc.


A valve/seal assembly 122 is disposed within a cavity 120A that is defined by a valve housing 120, which in the present embodiment, is defined by the first body portion 112A. The valve/seal assembly 122 includes a proximal seal 132 with a central hole for catheter passage, two slit valves 134A, 134B each with a slit arranged at a 90-degree offset with respect to the other, and a distal seal 135 with a central hole, also referred to herein as a sphincter seal.


The distal seal 135 includes on its distal surface a frustoconical portion 135A disposed about the seal central hole that is configured to provide a sphincter-like seal about the outer surface of a catheter when it extends through the valve/seal assembly. The frustoconical portion 135A is disposed such that any back-flowing fluid impinging on the frustoconical portion will cause the seal to secure itself about the outer surface of the catheter in an even tighter engagement, thus preventing backflow past the catheter outer surface when high fluid pressures are present, such as in the case of power injection. As mentioned, other valve/seal combinations can also be included in the valve/seal assembly.


In the present embodiment, the receiving cup 114 and portion of the conduit 118 proximal to the valve/seal assembly 122 both include a needle-impenetrable lining that prevents the distal end of a needle from gouging the surface when impinging thereon. This, in turn, prevents the undesirable creation of material flecks dug by the needle. Various suitable materials can be employed for the needle-impenetrable material, including glass, ceramic, metals, etc. In one embodiment, the components of the port 110 are all non-metallic such that the port is considered MRI-safe, by which the port does not produce undesired artifacts in MRI images taken of the patient when the port is in implanted therewithin.



FIG. 4 depicts additional features of the port 110 according to another embodiment. As shown, in the present embodiment the receiving cup 18 includes radiopaque indicia 128 to indicate a characteristic of the port 110. Here, the radiopaque indicia 128 includes a “C” and a “T” that are formed by a radiopaque material, such as tungsten, bismuth trioxide, etc., so as to be visible after port implantation via x-ray imaging technology. For instance, the radiopaque material can be formed as an insert that is insert-molded included in the port body, as an initially flowable material that is injected into a cavity of the port body before hardening, etc. In embodiments where the port body is metallic, the radiopaque indicia can be formed by etching, engraving, or otherwise producing a relative thickness difference between the indicia and the surrounding port body material so as to produce an x-ray-discernible contrast that shows up in an x-ray image.


In the present embodiment, the CT radiopaque indicia 128 indicate to an observer that the port is capable of power injection of fluids therethrough. In addition to this characteristic, other characteristics can be indicated by various other types of indicia as appreciated by one skilled in the art.


Further, in the present embodiment the top view of the port 110 of FIG. 4 indicates that the port body 112 in the region surrounding the receiving cup 114 defines a generally triangular shape, which can be palpated by a clinician after implantation and can indicate not only the location of the receiving cup, but also a particular characteristic of the port, such as its ability to be used for power injection. Of course, the receiving cup may define shapes other than triangular in other embodiments.



FIG. 4 further shows that distributed about the perimeter of the receiving cup 114 are three palpation features 126, namely, three suture plugs 126A disposed in corresponding holes defined in the port body 112. The suture plugs 126A include raised silicone bumps in the present embodiment and can serve to locate the position of the receiving cup 114 post-implantation when they are palpated by a clinician prior to needle insertion into the patient. Various other palpation features could be included with the port, in other embodiments.



FIG. 5 depicts details of a low-profile port 210 according to one embodiment, including a body 212 defining a concavely-shaped receiving cup 214 and an inlet port 216 positioned slightly off-center with respect to the receiving cup. A stem 224 is included as a fluid outlet.



FIG. 6 depicts the low-profile port 210 according to another embodiment, wherein the body 212 defining additional surface features, including a raised palpation feature 226 distal to the receiving cup 214. In light of FIGS. 5 and 6, it is thus appreciated that the port can be configured in a variety of shapes and configurations to provide a low-profile solution for providing vascular access. Note also that the receiving cup shape, design, and configuration can vary from is explicitly shown and described herein.



FIGS. 7A and 7B depict various details of a low-profile dual-body access port 310 according to one embodiment, wherein each of the port bodies 312 defines a receiving cup 314 that is laterally facing and includes an inlet port 316 leading to a conduit 318. The conduit 318 extends distally to a valve/seal assembly 322 disposed in a valve housing 320, which in the present embodiment, is defined by a portion of the body 312. The conduit 318 extends through the port 324. A compliant overmolded portion 324 covers portions of each body 312 of the port 310 and operably joins the bodies to one another. The bodies 312 can include any suitable material, including metal, thermoplastic, etc.



FIGS. 8A and 8B depict various details of a low-profile dual-body access port 410 according to one embodiment, wherein a port body 412 defines dual fluid paths. Each fluid path includes a receiving cup 414 defined by the body 412 and facing a substantially upward orientation from the perspective shown in FIGS. 8A and 8B. An inlet port 416 is included with each receiving cup 414 and defines the opening to a conduit 418. Each conduit 418 extends distally to a valve/seal assembly 422 disposed in a valve housing 420, which in the present embodiment, is defined by a portion of the body 412. The conduit 418 extends through the port 424. The body 412 can include any suitable material, including metal, thermoplastic, etc.


Reference is now made to FIGS. 9A-30, which depict various details of embodiments generally directed to vascular access devices, also referred to herein as access ports, for subcutaneous implantation within the body of a patient. The implanted access ports to be described are transcutaneously accessible by a catheter-bearing needle, such as a peripheral intravenous (“PIV”) catheter, so as to place the PIV catheter into fluid communication with the access port. A fluid outlet of the access port is operably connected to an in-dwelling catheter disposed within the vasculature of a patient, in one embodiment, to enable the infusion into and/or removal of fluids from the patient's vasculature to take place via the PIV catheter.


In accordance with one embodiment, the access port defines a relatively low profile so as to facilitate ease of placement within the subcutaneous tissue of the patient. Further, the access port is configured to provide a relatively large subcutaneous target to enable the PIV catheter or other suitable catheter-bearing needle to access the port without difficulty. In addition, the access port includes a valve/seal assembly to permit power injection of fluids through the access port. As before, possible applications for the access port described herein include administration of medicaments and other fluids to the patient, pheresis/apheresis, fluid aspiration, etc.


Reference is first made to FIGS. 9A-9G, which show various details of a vascular access device (also “access port” or “port”), generally designated at 510, in accordance with one embodiment. As shown, the port 510 includes a body 512 that is defined in the present embodiment by a first portion 512A and a second portion 512B (FIG. 9E). In the present embodiment the port body 512 includes a metal such as titanium, and as such, the second portion 512B is press fit into engagement with the first portion 512A to define the body, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc.


The port body first portion 512A defines in the present embodiment a substantially funnel-shaped receiving cup 514 for receiving and directing a catheter-bearing needle (FIG. 14A) to operably connect with the port 510, as described further below. In particular, the substantially funnel shape of the receiving cup 514 is configured to direct the catheter-bearing needle (FIG. 14A) impinging thereon toward an inlet port 516 that serves as an opening for a conduit 518 defined by the port body 512. The open and shallow nature of the receiving cup 514, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin, as seen in FIGS. 14A-14D. FIGS. 9B and 9C further show that the port 510 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the port after implantation. Note that palpation features can be included with the port body 512 to assist a clinician to locate and/or identify the port 510 via finger palpation after implantation under the skin of the patient, as with other embodiments herein. Further, in another embodiment a guide groove can be defined on the receiving cup 514 to be longitudinally aligned with the inlet port 516 of the conduit 518, similar to that shown in the access port 10 of FIG. 1A


Together with FIGS. 9A-9G, reference is also made to FIGS. 10 and 11. As best seen in FIG. 11, the port body 512 further defines the conduit 518 as a pathway into which a transcutaneously inserted catheter can pass so as to place the catheter in fluid communication with the port 510 and the indwelling catheter attached to the stem 524 thereof. As shown, the conduit 518 is in fluid communication with the receiving cup 514 via the inlet port 516. A first conduit portion 518A of the conduit 518 distally extends from the inlet port 516 in an angled downward direction from the perspective shown in FIG. 11 to a bend 530, where a second conduit portion 518B of the conduit extends substantially horizontally (from the perspective shown in FIG. 11) at a predetermined angle with respect to the first conduit portion. Note that predetermined angle at the bend 530 in one embodiment is about 34 degrees, but can vary from this in other embodiments, including angles less or more than 34 degrees in one embodiment. The magnitude of the predetermined angle at the bend 530 depends in one embodiment on various factors, including the size of the catheter and/or needle to be inserted into the port conduit, the size of the conduit itself, etc.


The conduit 518 then extends to and through a cavity 520A defined by a valve housing 520 of the port body 12 where a third conduit portion 518C extends to a distal open end of the stem 524 of the port 510. In the present embodiment the conduit 518 is sized so as to enable the catheter 40 (FIG. 14A) to pass therethrough to a predetermined point, as will be seen.


As mentioned, the valve housing 520, defined by portions of the first and second portions 512A, 512B of the body 512 defines a cavity 520A through which the conduit 518 passes and which houses a valve/seal assembly 522. The valve/seal assembly 522 includes a sealing element, or seal 532, which defines a central hole 532A (FIGS. 12A-12C) through which the catheter 40 (FIG. 14A) can pass, and a slit valve 534 including two intersecting slits 534A (FIGS. 13A-13C). The seal 532 and valve 534 are sandwiched together in one embodiment, with the seal 532 disposed proximal to the valve 534, and secured in place within the cavity 520A as shown in FIG. 11. The slits 534A of the slit valve 534 are orthogonally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible. Note that the valve 534 includes a central depression 535 to ease the transition of passage of the catheter 40 from the seal 532 to the valve.


The seal 532 and valve 534 of the valve/seal assembly 522 cooperate to enable fluid-tight passage therethrough of the catheter 40 (FIG. 14A) while also preventing backflow of fluid through the valve/seal assembly. Indeed, in one embodiment the seals disclosed herein prevent fluid flow around the external portion of the catheter when the catheter is disposed through the seal 532, while the valve 534 is suitable for preventing fluid flow when no catheter passes through them. As such, when the catheter 40 is not inserted therethrough the valve/seal assembly 522 seals to prevent passage of air or fluid through the conduit 518. In the present embodiment, the seal 532 and valve 534 are composed of silicone, such as SILASTIC® Q7-4850 liquid silicone rubber available from Dow Corning Corporation, though other suitably compliant materials can be employed. In one embodiment, silicone oil, such as NuSil Technology Med 400 silicone oil, is included with the seal 532 and valve 534 to enhance lubricity and extend component life. In another embodiment, the silicone oil is infused into the silicone.


The port 510 in the present embodiment includes an overmolded portion 536 that covers a majority portion of the port body 512. The overmolded portion 536 includes silicone, such as SILASTIC® Q7-4850 liquid silicone rubber or other suitably compliant material and surrounds the body 512 as shown so as to provide a relatively soft surface for the port 510 and reduce patient discomfort after port implantation within the patient body. The overmolded portion 536 includes in one embodiment predetermined suture locations 538, best seen in FIG. 9F, for suturing the port 510 to patient tissue, though sutures may be passed through other portions of the overmolded portion, if desired. The overmolded portion 536 further defines a relatively flat bottom surface 536A so as to provide a stable surface for the port 510 in its position within the tissue pocket after implantation into the patient body.



FIGS. 9C and 9G show that the first body portion 512A defines a securement ridge 537 that serves as an anchor to prevent relative movement between the overmolded portion 536 and the body 512. The securement ridge 537 can vary in shape, number, configuration, etc. Note that the overmolded portion 536 in one embodiment is molded in a molding process over the body 512. In another embodiment, the overmolded portion 536 is separately formed then adhesively attached to the body 512, such as via Med A adhesive. These and other configurations are therefore contemplated.



FIGS. 14A-14D depict details regarding the insertion of the catheter 40 disposed on the needle 42 into the port 510 (already subcutaneously implanted into the body of the patient), according to one embodiment. After locating the port 510 (optionally via through-skin palpation of palpation features, such as a top portion of the overmolded portion 536 and/or the receiving cup 514), a clinician uses the catheter-bearing needle 42 to pierce a skin surface and insert the needle until a distal tip 42B thereof impinges on a portion of the receiving cup 514, as shown in FIG. 14A. Note that, because of the orientation of the receiving cup 514 is angled substantially toward the skin surface, the needle 42 can impinge on the receiving cup at an insertion angle that is relatively steep, which facilitates ease of needle insertion into the body. Indeed, in one embodiment a needle inserted substantially orthogonally through the skin of the patient can impinge the receiving cup of the access port. In another, embodiment, the insertion angle of the needle 42 can be relatively shallow, similar to current insertion angles for IV catheters.


The needle 42 is manipulated by the clinician and guided by impingement on the receiving cup 514 until the needle distal tip 42B is guided to the inlet port 516. The needle 42 is then inserted through the inlet port 516 and into the first portion 518A of the conduit 518 until it is stopped by the bend 530, as seen in FIG. 14B. The needle 42 can then be proximally backed out a small distance, and the catheter 40 advanced over the needle such that the catheter bends and advances past the bend 530 into the second portion 518B of the conduit 518, as seen in FIG. 14C. Catheter advancement continues such that a distal end 40B of the catheter 40 advances into and past the hole 532A of the seal 532 and through both slits 534A of the slit valve 534 of the valve/seal assembly 522. Note that the length of the second conduit portion 518B is sufficient to enable the cross-sectional shape of the distal portion of the catheter 40 to return to a substantially round shape from the oval shape imposed thereon as a result of its passage through the conduit bend 530.


Once the distal end 40B of the catheter 40 has extended distally past the valve/seal assembly 522, further advancement is prevented by impingement of the catheter distal end against an annular stop surface 539 included in the third conduit portion 518C defined by the stem 524, as shown in FIG. 14D and in more detail in FIG. 11. In one embodiment, the stop surface 539 is defined as an annular shoulder and is sized so as to stop advancement of one size of catheter, such as 14 Gauge catheter, while allowing a 16 Gauge catheter to pass. In another embodiment, no stop surface is included in the conduit 518, thus enabling the catheter 40 to advance completely past the distal end of the stem 524, if desired. Note that the port conduit can be configured to accept one or more of a variety of catheter Gauge sizes, including 14 Gauge, 16 Gauge, 18 Gauge, etc.


Once the catheter 40 is positioned as shown in FIG. 14D, the needle 42 can be fully removed and fluid transfer through the catheter 40 and port 510 can commence, including infusion and/or aspiration through an indwelling catheter attached to the stem 524. (Note that the needle 42 can be removed at another stage of the catheter insertion procedure, in one embodiment.) Dressing of the catheter 40 can also occur as needed. Once fluid transfer is completed, the catheter 40 can be withdrawn proximally through the valve/seal assembly 522 and the conduit 518, then withdrawn through the surface of the skin and out of the patient.



FIG. 9F depicts that, in the present embodiment, the receiving cup 514 includes radiopaque indicia 528 to indicate a characteristic of the port 510. Here, the radiopaque indicia 528 includes an “IVCT” alphanumeric designation that is defined as a depression or recess into the titanium material forming the first body portion 512A so as to be visible after port implantation via x-ray imaging technology. The “IVCT” designation indicates that the port 510 is configured for power injection and is further configured to receive therein a peripheral IV catheter.


In another embodiment the radiopaque indicia 528 can be included by employing radiopaque material that can be formed as an insert that is insert-molded included in the port body, such as an initially flowable material that is injected into a cavity of the port body before hardening, etc. In embodiments where the port body is metallic, the radiopaque indicia can be formed by metal injection molding, machining, etching, engraving, or otherwise producing a relative thickness difference between the indicia and the surrounding port body material so as to produce an x-ray-discernible contrast that shows up in an x-ray image, similar to FIG. 1F.


In addition to above designation, other characteristics can be indicated by various other types of radiopaque indicia as appreciated by one skilled in the art.


As in other embodiments described herein, in one embodiment the perimeter of the receiving cup (or other suitable location) can include palpation features, such as three raised bumps in the overmolded portion 536 to assist in locating the position of the receiving cup 514 post-implantation when they are palpated by a clinician prior to needle insertion into the patient. Various other palpation features could be included with the port, in other embodiments, including disposal on the receiving cup itself, etc.



FIGS. 15A and 15B depict details of a guide device 550 that can be placed on the patient skin atop the implanted location of the port 510 shown in FIGS. 9A-9G to assist in guiding the needle 42 through the skin so as to impinge on the receiving cup 514, as desired. As shown, the guide device 550 includes a body 552 that defines a cavity 554 into which a portion of the subcutaneous implanted port 510 will reside when the guide device is pressed on the skin over the port. A notch 556 is included on the body 552, partially bordered by a ridge 558. The notch 556 enables the needle 42 to be passed therethrough so as to be inserted through the skin and into port 510. A marker line 560 is included on the ridge 548 to assist the clinician in placing the needle 42 at the proper orientation and location for impingement on the receiving cup 514, as desired. Note that the shape, size, and other configuration of the guide device can vary from what is shown and described herein.


Reference is now made to FIGS. 25A-25E, which show various details of a dual-lumen vascular access device, generally designated at 810, in accordance with one embodiment. As shown, the port 810 includes a body 812 that is defined in the present embodiment by two similarly shaped portions: a single first portion 812A and a single second portion 812B (FIG. 25C). In the present embodiment the port body first and second portions 812A, 812B include a metal such as titanium, and as such, the second portion is press fit into engagement with the first portion to define the body, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc., and can include other joining methods including adhesive, ultrasonic or other welding, interference fit, etc.


Both port body first portions 812A define in the present embodiment a substantially funnel-shaped receiving cup 814 for receiving and directing the catheter-bearing needle 42 (FIG. 14A) to operably connect with the port 810 in a manner similar to that already described above. In particular, the substantially funnel shape of each receiving cup 814 is configured to direct the catheter-bearing needle 42 impinging thereon toward an inlet port 816 that serves as an opening for a respective conduit 818 defined by the port body 812. The open and shallow nature of each receiving cup 814, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin and directed toward the subcutaneously implanted access port 810. FIG. 25B further shows that the access port 810 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the subcutaneous access port after implantation.


Note that, as already mentioned, palpation features can be included with the port body 812 in one embodiment to assist a clinician to locate and/or identify the port 810 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port. In another embodiment, a guide groove can be defined on the receiving cup 814 to be longitudinally aligned with the inlet port 816 of the conduit 818, as discussed in connection with the embodiment of FIGS. 1A-2. The guide groove can be defined as a depression with respect to adjacent portions of the surface of the receiving cup 814 and extend distally along the receiving cup surface from a proximal portion of the receiving cup so as to provide a guide path to guide the distal tip of the catheter-bearing needle toward the inlet port 816 once impingement of the needle into the guide groove is made. This in turn reduces the chance the needle will slide across and off the receiving cup 814 during insertion. Note that these and other similar features, though differing in shape and configuration, can also be included on the other ports disclosed herein.


As best seen in FIG. 25D, the port body 812 further defines the two conduits 818, each conduit serving as a pathway into which a transcutaneously inserted catheter can be partially inserted so as to place the catheter in fluid communication both with the port 810 and an indwelling dual-lumen catheter operably attached to two fluid outlets 824A of a stem 824 of the port. As shown, the conduit 818 of each port body first portion 812A is in fluid communication with its respective receiving cup 814 via the inlet port 816. A first conduit portion 818A of the conduit 818 distally extends from the inlet port 816 in an angled downward direction from the perspective shown in FIG. 25D to a conduit bend 830, where a second conduit portion 818B of the conduit extends at a predetermined angle with respect to the first conduit portion. Note that predetermined angle at the bend 830 in one embodiment is about 34 degrees, but can vary from this in other embodiments, including angles smaller or greater than 34 degrees in one embodiment. The magnitude of the predetermined angle at the bend 830 depends in one embodiment on various factors, including the size of the catheter and/or needle to be inserted into the port conduit, the size of the conduit itself, etc. Note also that the conduit bend 830 serves as a needle-stop feature, preventing the needle 42 from advancing along the conduit 818 past the bend 830.


The second conduit portion 818B of each port body first portion 812A distally extends to a cavity 820A defined by the press-fit junction of the port body first portion and the second portion 812B, as seen in FIG. 25D. Two third conduit portions 818C are defined by the second portion 812B of the port body 812 and extend from each of the cavities 820A in a partially arcuate fluid path to the distally-disposed fluid outlets 824A of the stem 824. In the present embodiment the conduit 818 is sized so as to enable the catheter 40 (FIG. 14A) to pass therethrough and past the cavity 820A.


As mentioned, the cavities 820A, each defined by the junction of the respective first portion 812A and the second portion 812B of the port body 812, each define a space through which the conduit 818 passes and in which is housed a valve/seal assembly 822. In the present embodiment and as best seen in FIGS. 25C and 25D, the valve/seal assembly 822 includes a sealing element, or seal 832, which defines a central hole 832A through which the catheter 40 (FIGS. 14A, 14D) can pass, and a slit valve 834 including two orthogonally intersecting slits 834A through which the catheter also passes. The seal 832 and slit valve 834 are sandwiched together in one embodiment, with the seal disposed proximal to the slit valve, and secured in place within the correspondingly sized cavity 820A as shown in FIG. 25D.


As mentioned, the slits 834A of the slit valve 834 are orthogonally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible, including the use of two single-slit valves sandwiched together with one another. Note that in the present embodiment the slit valve 834 includes a central depression (as in previous embodiments, such as is shown in FIG. 13A, for instance) to ease the transition of passage of the catheter 40 from the seal 832 to the valve. More than one seal and/or slit valve may be employed in the valve/seal assembly in other embodiments.


As with previous embodiments, the seal 832 and slit valve 834 of the valve/seal assembly 822 cooperate to enable fluid-tight passage therethrough of the catheter 40 (see, e.g., FIG. 14A) while also preventing backflow of fluid through the valve/seal assembly. Indeed, in one embodiment the seals disclosed herein prevent fluid flow around the external portion of the catheter when the catheter is disposed through the seal 832, while the valve 834 is suitable for preventing fluid flow when no catheter passes through them. As such, when the catheter 40 is not inserted therethrough the valve/seal assembly 822 seals to prevent passage of air or fluid through the conduit 818. In the present embodiment, the seal 832 and valve 834 are composed of silicone, such as SILASTIC® Q7-4850 liquid silicone rubber available from Dow Corning Corporation, though other suitably compliant materials can be employed. In one embodiment, silicone oil, such as NuSil Technology Med 400 silicone oil, is included with the seal 832 and valve 834 to enhance lubricity and extend component life. In another embodiment, the silicone oil is infused into the silicone.


The port 810 in the present embodiment includes an overmolded portion 836 that covers a portion of the port body 812, including a majority portion of each of the two first portions 818A. The overmolded portion 836 includes silicone, such as SILASTIC® Q7-4850 liquid silicone rubber or other suitably compliant material and surrounds the portions of the body 812 as shown in FIGS. 25A and 25B so as to provide a relatively soft surface for the port 810 and reduce patient discomfort after port implantation within the patient body. The overmolded portion 836 further enables a clinician to suture through one or more of various portions of the overmolded portion to enable the port 810 to be secured within a subcutaneous patient tissue pocket. The overmolded portion 836 further defines a relatively flat bottom surface 836A so as to provide a stable surface for the port 810 in its position within the tissue pocket after implantation into the patient body.



FIG. 25B shows that the first body portions 812A each define a securement ridge 837 that serves as an anchor to prevent relative movement between the overmolded portion 836 and the body 812. The securement ridge 837 can vary in shape, number, configuration, etc. Note that the overmolded portion 836 in one embodiment is molded in a molding process over the body 812. In another embodiment, the overmolded portion 836 is separately formed then adhesively attached to the body 812, such as via Med A adhesive. These and other configurations are therefore contemplated.



FIG. 25E shows that underside surfaces of the receiving cups 814 include a radiopaque indicia 828 configured to enable the port 810 to be radiographically identified after implantation into the patient body. In the present embodiment each of the indicia 828 includes the letters “IV” and “CT” to indicate suitability of the port 810 to receive peripheral IV catheters and that the port is capable of power injection of fluids therethrough. Of course, a variety of other indicia, including letters, numbers, symbols, etc., may be used.



FIGS. 26A-26D depict various details of the port 810 according to another embodiment, wherein the port body 812 defines a relatively slimmer profile than the embodiment shown in FIGS. 25A-25E, made possible by defining a cutout 870 on both receiving cups 814 of each first portion 812A of the port body 812. This enables the receiving cups 814 to reside relatively close to one another. The receiving cups 814 can be joined to one another along the cutouts 870 via welding, adhesive, forming the receiving cups together as a single component, etc.


In one embodiment, it is appreciated that the receiving cups 814 can be oriented in other configurations. FIG. 31 gives an example of this, wherein a partially exploded view of the port 810 is shown without the overmolded portion 836 present, and thus including the two first portions 812A and the second portion 812B. As shown, the receiving cups 814 are angled with respect to one another such that a perimeter 814A of a corresponding one of the receiving cups lies in an imaginary plane 890A that is non-parallel to another plane 890B in which a perimeter 814B of the other receiving cup lies. This is in contrast to another embodiment, such as that shown in FIG. 25A, wherein the receiving cups 814 substantially lie in a single imaginary plane. The configuration of FIG. 31 results in the receiving cups 814 being angled away from one another, as shown in FIG. 31, such that the non-parallel imaginary planes 890A and 890B form different positive angles, α and β respectively, with respect to an imaginary bisecting plane 890C between the receiving cups 814 (note that the first body portion 812A shown disconnected (for clarity) from the second body portion 812B is to be connected to the second body portion in substantially the same orientation as shown in FIG. 31). This, in turn, desirably results in a slightly lower height profile for the access port 810, and can also result in the needle 42 inserted therein residing relatively closer to the patient skin, in one embodiment. Note that the receiving cups can be angled in various different configurations in addition to what is shown and described herein.


Reference is now made to FIGS. 16A-21B, which depict details of a dual-lumen vascular access device, generally designated at 610, in accordance with one embodiment. As shown, the port 610 includes a body 612 that is defined in the present embodiment by a first portion 612A and a relatively smaller second portion 612B that is partially received within the first portion. In the present embodiment the port body first and second portions 612A, 612B include a metal such as titanium, and as such, the second portion is press fit into engagement with the first portion to define the body, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc., and can include other joining methods including adhesive, ultrasonic or other welding, interference fit, etc.


The port body first portion 612A defines in the present embodiment two substantially funnel-shaped receiving cups 614 for receiving and directing the catheter-bearing needle 42 (FIG. 14A) to operably connect with the port 610 in a manner similar to that already described above. The receiving cups 614 in the present embodiment are disposed so as to be substantially aligned along a longitudinal axis of the port 610, though other positional arrangements for the receiving cups are possible, including side-by-side, spaced-apart, staggered, etc.


In particular, the substantially funneled-shape of each receiving cup 614 is configured to direct the catheter-bearing needle 42 impinging thereon toward an inlet port 616 that serves as an opening for a respective one of two conduits 618 defined by the port body 612, one conduit for each receiving cup. The open and shallow nature of each receiving cup 614, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin and directed toward the subcutaneously implanted access port 610. FIGS. 16C and 16F further show that the access port 610 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the subcutaneous access port after implantation.


The port body 612 further defines a palpation feature 637, here configured as a raised surface interposed between the longitudinally aligned receiving cups 614. As mentioned above, the palpation feature 637 is included with the port body 612 to assist a clinician to locate and/or identify the port 610 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port. In another embodiment, a guide groove can be defined on each receiving cup 614 to be longitudinally aligned with the inlet port 616 of the conduit 618, as in previous embodiments.


As best seen in FIGS. 17A, 17B, and 19, the port body 612 further defines the above-mentioned two conduits 618, each conduit serving as a pathway into which a transcutaneously inserted catheter can be partially inserted so as to place the catheter in fluid communication both with the port 610 and an indwelling dual-lumen catheter operably attached to two fluid outlets 624A of a stem 624 of the port. As shown, the two conduits 618 of the port body first portion 612A are in fluid communication with their respective receiving cup 614 via the corresponding inlet port 616. A first conduit portion 618A of each conduit 618 distally extends from the respective inlet port 616 in an angled downward direction from the perspective shown in FIG. 17A to a conduit bend 630 (FIG. 19), where the first conduit portion extends distally at a predetermined angle with respect to the first conduit portion proximal to the conduit bend. The magnitude of the predetermined angle at the bend 630 depends in one embodiment on various factors, including the size of the catheter and/or needle to be inserted into the port conduit, the size of the port and the conduit itself, etc. Note also that the conduit bend 630 serves as a needle-stop feature, preventing the needle 42 from advancing along the conduit 618 past the bend 630.


The first portion 618A of the relatively more distal of the two receiving cups 614 extends to a cavity 620A defined by and proximate to the distal portion of the first portion 612A of the port body 612, as best seen in FIGS. 18 and 19. The first portion 618A of the relatively more proximal of the two receiving cups 614 also extends to a cavity 620A that is defined by, but relatively more proximally distant from, the distal portion of the first portion 612A of the port body 612 (FIGS. 18 and 19). A second conduit portion 618B is defined for this latter conduit 618 by the second portion 612A of the port body 612, as seen in FIGS. 17A and 17B and extends distally from its respective cavity 620A until joining with a third conduit portion 618C defined by the second portion 612A of the port body, which extends through the second portion and the stem 624 until terminating at a respective one of the fluid outlets 624A (FIG. 20).


The conduit 618 for the relatively more distal receiving cup 614 extends from the cavity 620A to a third conduit portion 618C defined by the second portion 612A of the port body 612, as seen in FIG. 20, which extends through the second portion and the stem 624 until terminating at a respective one of the fluid outlets 624A. In this way, fluid pathways are defined for each receiving cup 614 from the inlet port 616 to the stem fluid outlet 624A, as depicted in FIGS. 21A and 21B. In the present embodiment the conduit 618 is sized so as to enable the catheter 40 (FIG. 14A) to pass therethrough past the cavity 620A.


As mentioned, the cavities 620A, each disposed in the fluid pathway defined by the various portions of the conduits 618, each define a space through which the conduit 618 passes and in which is housed a valve/seal assembly 622. In the present embodiment and as best seen in FIGS. 17A-18, each valve/seal assembly 622 includes a sealing element, or seal 632, which defines a central hole 632A (FIG. 21B) through which the catheter 40 (FIGS. 14A, 14D) can pass, and two adjacently placed slit valves 634, each slit valve including a single slit 634A (with the valves being arranged such that the slits are orthogonal to one another), through which the catheter also passes. The seal 632 and slit valves 634 are sandwiched together in one embodiment, with the seal disposed proximal to the slit valve, and secured in place within the correspondingly sized cavity 620A as shown in FIGS. 17A and 17B. In another embodiment, the valve/seal assembly includes a single seal and a single, dual-slit valve, as in previous embodiments.


In the present embodiment, the seal 632 and valves 634 are composed of silicone, such as SILASTIC® Q7-4850 liquid silicone rubber available from Dow Corning Corporation, though other suitably compliant materials can be employed. In one embodiment, silicone oil, such as NuSil Technology Med 400 silicone oil, is included with the seal 632 and valves 634 to enhance lubricity and extend component life. In another embodiment, the silicone oil is infused into the silicone. Also, and as has been mentioned with other embodiments, other seal/valve configurations can also be employed in the port 610.


Reference is now made to FIGS. 22A-24, which show various details of a dual-lumen vascular access device, generally designated at 710, in accordance with one embodiment. As shown, the port 710 includes a body 712 that is defined in the present embodiment by a first portion 712A defining the majority of the external portion of the port body and a second portion 712B that is matable to the first portion. In the present embodiment the port body first and second portions 712A, 712B include a metal such as titanium, and as such, the second portion is press fit into engagement with the first portion to define the body 212, though it is appreciated that the port body can include a variety of other materials, including metals, thermoplastics, ceramics, etc., and can include other joining methods including adhesive, ultrasonic or other welding, interference fit, etc.


The port body first portion 712A defines in the present embodiment two substantially concavely-shaped receiving cups 714, side-by-side in a spaced-apart arrangement, for receiving and directing the catheter-bearing needle 42 (FIG. 14A) to operably connect with the port 710 in a manner similar to that already described above. In particular, the substantially concave shape of each receiving cup 714 is configured to direct the catheter-bearing needle 42 impinging thereon toward an inlet port 716 that serves as an opening for a respective conduit 718 defined by the port body 712.


The open and shallow nature of each receiving cup 714, angled toward the skin surface of the patient enables the receiving cup to present a large, easily accessible target for the needle when introduced into the skin and directed toward the subcutaneously implanted access port 710. FIGS. 22A and 22B further show that the access port 710 defines a relatively low profile height, which enables relatively shorter needle lengths to be used for accessing the subcutaneous access port after implantation. FIG. 22C depicts details of a bottom portion of the port body 712. Note that in this and other embodiments, the receiving cups can define different surfaces, including funnel-shaped, concave-shaped, hemispherical, etc.


The port body 712 includes a plurality of palpation features 737, here implemented as ridges extending distally from the receiving cups 714, to assist a clinician to locate and/or identify the port 710 via finger palpation after implantation under the skin of the patient. Note that a variety of sizes, configurations, numbers, etc., of palpation features can be included on the port.


As best seen in FIGS. 23 and 24, the port body 712 further defines the two conduits 718, each conduit serving as a pathway into which a transcutaneously inserted catheter can be partially inserted so as to place the catheter in fluid communication both with the port 710 and an indwelling dual-lumen catheter operably attached to two fluid outlets 724A of a stem 724 of the port. As shown, each of the two conduits 718 of the port body first portion 712A is in fluid communication with its respective receiving cup 714 via the inlet port 716 and extends distally to a valve/seal assembly 722 disposed in a cavity cooperatively defined by the junction of the port body first portion 712A and the second portion 712B. As with other embodiments herein, each conduit 718 distally extends from the respective inlet port 716 in an angled downward direction from the perspective shown in FIG. 23 to a conduit bend before continuing to the cavity wherein is disposed the valve/seal assembly. Note that the conduit bend can desirably serve as a needle-stop feature, preventing the needle 42 from advancing along the conduit 718 past the bend. The conduits distally extend past the valve/seal assembly 722 and through the port body second portion 712B to the fluid outlets of the stem 724. In the present embodiment the conduit 718 is sized so as to enable the catheter 40 (FIG. 14A) to pass therethrough past the valve/seal assembly 722.


As mentioned, the cavities, each defined by the junction of the respective first portion 712A and the second portion 712B of the port body 712, each define a space through which the conduit 718 passes and in which is housed the valve/seal assembly 722. In the present embodiment and as best seen in FIGS. 23 and 24, each of the two valve/seal assemblies 722 includes a sealing element, or seal 732, which defines a central hole through which the catheter 40 (FIGS. 14A, 14D) can pass, and two slit valves 734, each including a single slit and positioned adjacent each other such that the slits are substantially orthogonal to one another, through which the catheter also passes. The seal 732 and the slit valves 734 are sandwiched together in one embodiment, with the seal disposed proximal to the slit valves, and secured in place within the correspondingly sized cavity as shown in FIGS. 23 and 24.


As mentioned, the slits of the slit valves 734 are orthogonally offset from one another by about 90 degrees in the present embodiment, though other relationships are possible, including the use of a single slit valve including two orthogonal slits. These and other modifications to this and the other valve/seal assembly embodiments herein are therefore contemplated.


As with previous embodiments, the seal 732 and slit valves 734 of the valve/seal assembly 722 cooperate to enable fluid-tight passage therethrough of the catheter 40 (see, e.g., FIG. 14A) while also preventing backflow of fluid through the valve/seal assembly. Indeed, in one embodiment the seals disclosed herein prevent fluid flow around the external portion of the catheter when the catheter is disposed through the seal 732, while the valve 734 is suitable for preventing fluid flow when no catheter passes through them. As such, when the catheter 40 is not inserted therethrough the valve/seal assembly 722 seals to prevent passage of air or fluid through the conduit 718. In the present embodiment, the seal 732 and valve 734 are composed of silicone, such as SILASTI©® Q7-4850 liquid silicone rubber available from Dow Corning Corporation, though other suitably compliant materials can be employed. In one embodiment, silicone oil, such as NuSil Technology Med 400 silicone oil, is included with the seal 732 and valve 734 to enhance lubricity and extend component life. In another embodiment, the silicone oil is infused into the silicone.


Though not explicitly shown here, the port 710, as with other embodiments herein, can include radiopaque indicia configured to enable the port to be radiographically identified after implantation into the patient body. In one embodiment, the indicia include the letters “IV” and “CT” to indicate suitability of the port 710 to receive peripheral IV catheters and that the port is capable of power injection of fluids therethrough. Of course, a variety of other indicia, including letters, numbers, symbols, etc., may be used.


Though single and dual-port configurations have been described herein, it is appreciated that ports including more than two receiving cups are contemplated. Note also that certain of the receiving cups described herein are described as funnel shaped, while other receiving cups are described herein as concavely shaped. It is noted that that the receiving cups can interchangeably include aspects of one or the other, or both, of these receiving cup shapes, according to a particular embodiment.



FIGS. 27-30 depict details of various possible configurations for the valve/seal assembly, according to example embodiments. In FIG. 27, the seal 32 includes a central depression 380, similar but relatively steeper than the depression 35 of the valve 34. In FIG. 28, two seals are included—the seal 32 and a second seal 382 interposed between the seal 32 and the valve 34. The second seal 382 includes a central hole 382A that includes a diameter smaller relative to the hole 32A of the seal 32. FIG. 29 includes a similar configuration, but the hole 382A is similar in size to the hole 32A. A small central depression 35 is included on the valve 34 in both FIG. 28 and FIG. 29.


In FIG. 30, the seal 32 includes a relatively small-diameter central hole 32A, and the valve 34 includes a relatively large central depression 35. Note that the valve/seal assemblies shown in FIGS. 27-30 are oriented in the figures such that the catheter pierces the seals and valves in a direction corresponding from the top of the page toward the bottom of the page.


Embodiments of the invention may be embodied in other specific forms without departing from the spirit of the present disclosure. The described embodiments are to be considered in all respects only as illustrative, not restrictive. The scope of the embodiments is, therefore, indicated by the appended claims rather than by the foregoing description. All changes that come within the meaning and range of equivalency of the claims are to be embraced within their scope.

Claims
  • 1. A low-profile access port for subcutaneous placement in a patient, comprising: a body including: a receiving cup formed of metal, the receiving cup comprising: a funnel shape to direct a catheter-bearing needle into an inlet port defined in the receiving cup; andrecesses forming indicia to enable identification of the access port via x-ray imaging;a conduit extending between the inlet port and a fluid outlet defined by a stem of the body, the conduit defining a bend distal to the inlet port configured to prevent further distal advancement of the needle; anda valve/seal assembly disposed in the conduit distal to the bend, the valve/seal assembly configured to enable passage of the catheter of the catheter-bearing needle therethrough, the valve/seal assembly including: a seal component defining a central hole; anda valve including two intersecting slits.
  • 2. The access port as defined in claim 1, further comprising: a stop surface defined in the conduit distal to the valve/seal assembly, the stop surface configured to prevent further distal advancement of the catheter after passage of the catheter through the valve/seal assembly.
  • 3. The access port as defined in claim 1, wherein the two intersecting slits of the valve are orthogonally defined with respect to one another.
  • 4. The access port as defined in claim 1, wherein the catheter includes a substantially circular cross-sectional shape, wherein the seal component and the valve include silicone, and wherein a length of the conduit between the bend and the valve/seal assembly is sufficient to enable a distal end of the catheter to return to the substantially circular cross-sectional shape after passage past the bend and prior to passage of the distal end of the catheter through the valve/seal assembly.
  • 5. The access port as defined in claim 4, wherein the valve includes a central depression, wherein at least one of the seal component and the valve include silicone oil, and wherein the catheter is configured as one of a 14 Ga., a 16 Ga., and an 18 Ga. size catheter.
  • 6. The access port as defined in claim 1, wherein the metal of the receiving cup includes titanium.
  • 7. The access port as defined in claim 1, wherein the recesses form alphanumeric characters.
  • 8. The access port as defined in claim 7, wherein the alphanumeric characters are “IVCT”.
  • 9. The access port as defined in claim 1, further including an overmold portion covering the conduit, the overmold portion including a compliant material.
  • 10. The access port as defined in claim 9, wherein the overmold portion includes silicone and further includes a suture location configured to enable a clinician to suture the access port within a tissue pocket in a body of the patient.
  • 11. The access port as defined in claim 9, wherein the body of the access port further includes a securement ridge extending along an exterior surface of the conduit configured to provide an anchor for the overmold portion.
  • 12. A guide device for use in guiding a catheter-bearing needle into the access port disclosed in claim 1 when the access port is subcutaneously implanted into a patient, the guide device comprising: a body defining a cavity, the cavity configured to receive therein a portion of the subcutaneously implanted access port when the guide device is placed on a skin surface of the patient over the implanted access port; anda notch defined in the body, the notch positioned to enable the catheter-bearing needle inserted through the notch to pierce the skin surface of the patient and operably enter the access port.
  • 13. The guide device as defined in claim 12, further comprising a ridge defined about at least a portion of a perimeter of the notch and a marker line defined proximate the notch, the marker line indicating where the catheter-bearing needle is to be inserted through the notch.
  • 14. A low-profile access port for subcutaneous placement in a patient, comprising: a body including: first and second receiving cups, each of the first and second receiving cups being funnel shaped to direct a catheter-bearing needle into a corresponding one of a first and a second inlet port respectively defined in the first and second receiving cups, the first and second receiving cups being disposed in a side-by-side arrangement, the first receiving cup having a perimeter lying in a first plane, the second receiving cup having a perimeter lying in a second plane, the first plane forming a first angle with respect to a bisecting plane between the first receiving cup and the second receiving cup, the second plane forming a second angle with respect to the bisecting plane, the second angle different from the first angle, the first angle and the second angle measured above the first plane and the second plane;first and second conduits in communication with a corresponding one of the first and second inlet ports, each of the first and second conduits in fluid communication with a fluid outlet defined by a stem of the body; andfirst and second valve/seal assemblies disposed in a corresponding one of the first and second conduits, each of the first and second valve/seal assemblies including a seal defining a central hole and at least one valve including a slit.
  • 15. The access port as defined in claim 14, wherein the first and second receiving cups are disposed on opposite sides of a longitudinal axis of the body.
  • 16. The access port as defined in claim 14, wherein the body includes a first portion and a second portion that are joined to one another.
  • 17. The access port as defined in claim 16, wherein each of the first and second valve/seal assemblies is interposed in a respective cavity defined between the first portion and the second portion of the body.
  • 18. The access port as defined in claim 14, wherein the first and second receiving cups are in physical contact with one another.
  • 19. The access port as defined in claim 18, wherein the first and second receiving cups include cutouts, the first and second receiving cups in physical contact at their respective cutouts.
  • 20. The access port as defined in claim 14, further including a compliant overmolded portion disposed about at least a portion of the body of the access port.
  • 21. The access port as defined in claim 14, wherein each of the first and second receiving cups are made of metal, and wherein each of the first and second receiving cups includes recesses forming indicia configured to enable identification of the access port via x-ray imaging.
  • 22. The access port as defined in claim 21, wherein the recesses form alphanumeric characters configured to indicate the access port is capable of power injection of fluid therethrough.
  • 23. The access port as defined in claim 22, wherein the alphanumeric characters on the first receiving cup are “IV” and on the second receiving cup are “CT”.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a continuation-in-part of U.S. patent application Ser. No. 14/162,113, filed Jan. 23, 2014, and titled “Low-Profile Access Port,” which claims the benefit of U.S. Provisional Application No. 61/755,913, filed Jan. 23, 2013, and titled “Low Profile Access Port.” This application also claims the benefit of the following: U.S. Provisional Application No. 62/421,131, filed Nov. 11, 2016, and titled “Low-Profile Vascular Access Device; and U.S. Provisional Application No. 62/552,681, filed Aug. 31, 2017, and titled “Low-Profile Single and Dual Vascular Access Device.” Each of the aforementioned applications is incorporated herein by reference in its entirety.

US Referenced Citations (337)
Number Name Date Kind
3951147 Tucker et al. Apr 1976 A
4184489 Burd Jan 1980 A
4222374 Sampson et al. Sep 1980 A
4400169 Stephen Aug 1983 A
4447237 Frisch et al. May 1984 A
4496349 Cosentino Jan 1985 A
4543088 Bootman et al. Sep 1985 A
4559039 Ash et al. Dec 1985 A
4569675 Prosl et al. Feb 1986 A
4673394 Fenton, Jr. et al. Jun 1987 A
4692146 Hilger Sep 1987 A
4695273 Brown Sep 1987 A
4704103 Stober et al. Nov 1987 A
4710174 Moden et al. Dec 1987 A
4762517 McIntyre et al. Aug 1988 A
4767410 Moden et al. Aug 1988 A
4772270 Wiita et al. Sep 1988 A
4772276 Wiita et al. Sep 1988 A
4778452 Moden et al. Oct 1988 A
4790826 Elftman Dec 1988 A
4802885 Weeks et al. Feb 1989 A
4804054 Howson et al. Feb 1989 A
4820273 Reinicke Apr 1989 A
4861341 Woodburn Aug 1989 A
4886501 Johnston et al. Dec 1989 A
4892518 Cupp Jan 1990 A
4897081 Poirier et al. Jan 1990 A
4904241 Bark Feb 1990 A
4915690 Cone et al. Apr 1990 A
4929236 Sampson May 1990 A
4963133 Whipple Oct 1990 A
4978338 Melsky et al. Dec 1990 A
5013298 Moden et al. May 1991 A
5041098 Loiterman et al. Aug 1991 A
5045060 Melsky et al. Sep 1991 A
5045064 Idriss Sep 1991 A
5053013 Ensminger et al. Oct 1991 A
5057084 Ensminger Oct 1991 A
5084015 Moriuchi Jan 1992 A
5090954 Geary Feb 1992 A
5108377 Cone et al. Apr 1992 A
5137529 Watson et al. Aug 1992 A
5147321 Slonina Sep 1992 A
5147483 Melsky et al. Sep 1992 A
5158547 Doan et al. Oct 1992 A
5167633 Mann et al. Dec 1992 A
5167638 Felix Dec 1992 A
5171228 McDonald Dec 1992 A
5178612 Fenton, Jr. Jan 1993 A
5180365 Ensminger et al. Jan 1993 A
5185003 Brethauer Feb 1993 A
5201715 Masters Apr 1993 A
5203771 Melker et al. Apr 1993 A
5213574 Fucker May 1993 A
D337637 Tucker Jul 1993 S
5226879 Ensminger et al. Jul 1993 A
5263930 Ensminger Nov 1993 A
5266071 Elftman Nov 1993 A
5281199 Ensminger et al. Jan 1994 A
5281205 McPherson Jan 1994 A
5318545 Tucker Jun 1994 A
5336194 Polaschegg et al. Aug 1994 A
5350360 Ensminger Sep 1994 A
5360407 Leonard et al. Nov 1994 A
5387192 Glantz et al. Feb 1995 A
5395324 Hinrichs et al. Mar 1995 A
5399168 Wadsworth, Jr. et al. Mar 1995 A
5405325 Labs Apr 1995 A
5409463 Thomas Apr 1995 A
5417656 Ensminger et al. May 1995 A
5421814 Geary Jun 1995 A
5423334 Jordan Jun 1995 A
5476451 Ensminger et al. Dec 1995 A
5503630 Ensminger et al. Apr 1996 A
5514103 Srisathapat et al. May 1996 A
5520643 Ensminger May 1996 A
5527277 Ensminger et al. Jun 1996 A
5527278 Ensminger et al. Jun 1996 A
5531684 Ensminger et al. Jul 1996 A
5542923 Ensminger et al. Aug 1996 A
5554117 Ensminger et al. Sep 1996 A
5556381 Ensminger et al. Sep 1996 A
5558641 Glantz et al. Sep 1996 A
5562617 Finch, Jr. et al. Oct 1996 A
5562618 Cai et al. Oct 1996 A
5575770 Melsky et al. Nov 1996 A
5578070 Utterberg Nov 1996 A
5607393 Ensminger et al. Mar 1997 A
5613945 Cai et al. Mar 1997 A
5620419 Lui Apr 1997 A
5632729 Cai et al. May 1997 A
5647855 Frooskin Jul 1997 A
5695490 Flaherty et al. Dec 1997 A
5702363 Flaherty Dec 1997 A
5704915 Melsky Jan 1998 A
5713858 Heruth et al. Feb 1998 A
5718682 Fucker Feb 1998 A
5725507 Petrick Mar 1998 A
5741228 Lambrecht Apr 1998 A
5743873 Cai et al. Apr 1998 A
5758667 Slettenmark Jun 1998 A
5769823 Otto Jun 1998 A
5792104 Speckman et al. Aug 1998 A
5810789 Powers et al. Sep 1998 A
5833654 Powers et al. Nov 1998 A
5848989 Villani Dec 1998 A
5906596 Tallarida May 1999 A
5908414 Otto et al. Jun 1999 A
5913998 Butler et al. Jun 1999 A
5925017 Kriesel et al. Jul 1999 A
5931829 Burbank et al. Aug 1999 A
5944688 Lois Aug 1999 A
5947953 Ash et al. Sep 1999 A
5951512 Dalton Sep 1999 A
5954687 Baudino Sep 1999 A
5954691 Prosl Sep 1999 A
5968011 Larsen et al. Oct 1999 A
5989206 Prosl et al. Nov 1999 A
5989216 Johnson et al. Nov 1999 A
5989239 Finch et al. Nov 1999 A
6007516 Burbank et al. Dec 1999 A
6013051 Nelson Jan 2000 A
6013058 Prosl et al. Jan 2000 A
6022335 Ramadan Feb 2000 A
6039712 Fogarty et al. Mar 2000 A
6042569 Finch, Jr. et al. Mar 2000 A
6053901 Finch, Jr. et al. Apr 2000 A
6056717 Finch et al. May 2000 A
6086555 Eliasen et al. Jul 2000 A
6090067 Carter Jul 2000 A
6090068 Chanut Jul 2000 A
6102884 Squitieri Aug 2000 A
6120492 Finch et al. Sep 2000 A
6190349 Ash et al. Feb 2001 B1
6190352 Haarala et al. Feb 2001 B1
6206851 Prosl Mar 2001 B1
6213973 Eliasen et al. Apr 2001 B1
D445175 Bertheas Jul 2001 S
6287293 Jones et al. Sep 2001 B1
6332874 Eliasen et al. Dec 2001 B1
6350251 Prosl et al. Feb 2002 B1
6352521 Prosl Mar 2002 B1
6398764 Finch, Jr. et al. Jun 2002 B1
6436084 Finch et al. Aug 2002 B1
6438397 Bosquet et al. Aug 2002 B1
6459917 Gowda et al. Oct 2002 B1
6478783 Moorehead Nov 2002 B1
6482197 Finch et al. Nov 2002 B2
6494867 Elver et al. Dec 2002 B1
6506182 Estabrook et al. Jan 2003 B2
6527754 Tallarida et al. Mar 2003 B1
6540717 Sherry Apr 2003 B2
6582409 Squitieri Jun 2003 B1
6607504 Haarala et al. Aug 2003 B2
6620118 Prosl et al. Sep 2003 B1
6695832 Schon et al. Feb 2004 B2
6699218 Flaherty et al. Mar 2004 B2
6719749 Schweikert et al. Apr 2004 B1
6726711 Langenbach et al. Apr 2004 B1
6758841 Haarala et al. Jul 2004 B2
6783522 Fischell Aug 2004 B2
6852106 Watson et al. Feb 2005 B2
6881211 Schweikert et al. Apr 2005 B2
6929631 Brugger et al. Aug 2005 B1
6960185 Adaniya et al. Nov 2005 B2
6962580 Adams et al. Nov 2005 B2
6997914 Smith et al. Feb 2006 B2
7018374 Schon et al. Mar 2006 B2
7056316 Burbank et al. Jun 2006 B1
7070591 Adams et al. Jul 2006 B2
7083648 Yu et al. Aug 2006 B2
7108686 Burke et al. Sep 2006 B2
7131962 Estabrook et al. Nov 2006 B1
7223257 Shubayev et al. May 2007 B2
7261705 Edoga et al. Aug 2007 B2
7311702 Tallarida et al. Dec 2007 B2
7322953 Redinger Jan 2008 B2
D562443 Zinn et al. Feb 2008 S
7347843 Adams et al. Mar 2008 B2
7351233 Parks Apr 2008 B2
7396359 Derowe et al. Jul 2008 B1
D574950 Zawacki et al. Aug 2008 S
D578203 Bizup Oct 2008 S
7445614 Bunodiere et al. Nov 2008 B2
D582032 Bizup et al. Dec 2008 S
7497850 Halili Mar 2009 B2
D612479 Zawacki et al. Mar 2010 S
7699821 Nowak Apr 2010 B2
7704225 Kantrowitz Apr 2010 B2
7708722 Glenn May 2010 B2
7713251 Tallarida et al. May 2010 B2
7731680 Patton Jun 2010 B2
7762999 Byrum Jul 2010 B2
7824365 Haarala et al. Nov 2010 B2
7846139 Zinn et al. Dec 2010 B2
7850666 Schon et al. Dec 2010 B2
7909804 Stats Mar 2011 B2
7959615 Stats et al. Jun 2011 B2
7972315 Birk et al. Jul 2011 B2
7981094 Chelak Jul 2011 B2
D650475 Smith et al. Dec 2011 S
8075536 Gray et al. Dec 2011 B2
8079990 Powley et al. Dec 2011 B2
8147455 Butts et al. Apr 2012 B2
8152792 Kornel Apr 2012 B1
8257325 Schweikert et al. Sep 2012 B2
8277425 Girard et al. Oct 2012 B2
8328768 Quigley et al. Dec 2012 B2
8337464 Young et al. Dec 2012 B2
8337465 Young et al. Dec 2012 B2
8337470 Prasad et al. Dec 2012 B2
8343108 Rosenberg et al. Jan 2013 B2
8364230 Simpson et al. Jan 2013 B2
8377034 Tallarida et al. Feb 2013 B2
8425416 Brister et al. Apr 2013 B2
8425476 Glenn Apr 2013 B2
8480560 Vendely Jul 2013 B2
8550981 Woodruff et al. Oct 2013 B2
8574204 Bourne et al. Nov 2013 B2
RE44639 Squitieri Dec 2013 E
8622980 Zinn Jan 2014 B2
8690815 Porter et al. Apr 2014 B2
8690816 Dakin et al. Apr 2014 B2
8738151 Nelson May 2014 B2
8979806 Saab Mar 2015 B2
9033931 Young et al. May 2015 B2
9061129 Lauer Jun 2015 B2
9072880 Phillips et al. Jul 2015 B2
9072881 Dalton et al. Jul 2015 B2
9078982 Lane et al. Jul 2015 B2
9089395 Honaryar Jul 2015 B2
9095665 Pages et al. Aug 2015 B2
9138563 Glenn Sep 2015 B2
9168365 Bourne et al. Oct 2015 B2
9174037 Schutz et al. Nov 2015 B2
9179901 Young et al. Nov 2015 B2
9180248 Moberg et al. Nov 2015 B2
9474888 Wiley et al. Oct 2016 B2
9579496 Evans et al. Feb 2017 B2
9987467 Jochum Jun 2018 B2
10207095 Barron et al. Feb 2019 B2
10272236 Davey Apr 2019 B2
10463845 Stats et al. Nov 2019 B2
D870264 Fedor et al. Dec 2019 S
D885557 Fedor et al. May 2020 S
20010041870 Gillis et al. Nov 2001 A1
20010056266 Tallarida et al. Dec 2001 A1
20030023208 Osypka et al. Jan 2003 A1
20030181878 Tallarida et al. Sep 2003 A1
20040054352 Adams et al. Mar 2004 A1
20040073196 Adams et al. Apr 2004 A1
20040199129 DiMatteo Oct 2004 A1
20040204692 Eliasen Oct 2004 A1
20040254536 Conlon et al. Dec 2004 A1
20040254537 Conlon et al. Dec 2004 A1
20050075614 Bunodiere et al. Apr 2005 A1
20050113806 De Carvalho et al. May 2005 A1
20050131352 Conlon et al. Jun 2005 A1
20050148956 Conlon et al. Jul 2005 A1
20050148957 Girard et al. Jul 2005 A1
20050171502 Daly et al. Aug 2005 A1
20050203484 Nowak Sep 2005 A1
20050209573 Brugger et al. Sep 2005 A1
20050256451 Adams et al. Nov 2005 A1
20050277899 Conlon et al. Dec 2005 A1
20060084929 Eliasen Apr 2006 A1
20060089619 Ginggen Apr 2006 A1
20060100592 Eliasen May 2006 A1
20060173424 Conlon Aug 2006 A1
20060178617 Adams et al. Aug 2006 A1
20060178647 Stats Aug 2006 A1
20060184142 Schon et al. Aug 2006 A1
20060217659 Patton Sep 2006 A1
20060217673 Schulze et al. Sep 2006 A1
20060224129 Beasley et al. Oct 2006 A1
20060247584 Sheetz et al. Nov 2006 A1
20060264898 Beasley et al. Nov 2006 A1
20060271012 Canaud et al. Nov 2006 A1
20070049806 Adams et al. Mar 2007 A1
20070073250 Schneiter Mar 2007 A1
20070078391 Wortley et al. Apr 2007 A1
20070078416 Eliasen Apr 2007 A1
20070083156 Muto Apr 2007 A1
20070161958 Glenn Jul 2007 A1
20070179456 Glenn Aug 2007 A1
20070208313 Conlon et al. Sep 2007 A1
20070219510 Zinn et al. Sep 2007 A1
20070232997 Glenn Oct 2007 A1
20070233017 Zinn et al. Oct 2007 A1
20070233018 Bizup et al. Oct 2007 A1
20070255234 Haase et al. Nov 2007 A1
20070270770 Bizup Nov 2007 A1
20070276344 Bizup et al. Nov 2007 A1
20070282308 Bell Dec 2007 A1
20080048855 Berger Feb 2008 A1
20080086075 Isik et al. Apr 2008 A1
20080108942 Brister et al. May 2008 A1
20080114308 di Palma et al. May 2008 A1
20080132946 Mueller Jun 2008 A1
20080208236 Hobbs et al. Aug 2008 A1
20080281279 Hoendervoogt et al. Nov 2008 A1
20080319399 Schweikert et al. Dec 2008 A1
20080319405 Bizup Dec 2008 A1
20090024024 Zinn Jan 2009 A1
20090024098 Bizup Jan 2009 A1
20090099526 Powley Apr 2009 A1
20090105688 McIntyre Apr 2009 A1
20090118683 Hanson May 2009 A1
20090156928 Evans et al. Jun 2009 A1
20090192467 Hansen et al. Jul 2009 A1
20090204074 Powers et al. Aug 2009 A1
20090221976 Linden Sep 2009 A1
20090259164 Pages et al. Oct 2009 A1
20100042073 Oster et al. Feb 2010 A1
20100121283 Hamatake et al. May 2010 A1
20100298684 Leach et al. Nov 2010 A1
20110118677 Wiley et al. May 2011 A1
20110257577 Lane et al. Oct 2011 A1
20110264058 Linden et al. Oct 2011 A1
20110319728 Petisce et al. Dec 2011 A1
20120172711 Kerr et al. Jul 2012 A1
20120283518 Hart Nov 2012 A1
20130030348 Lauer Jan 2013 A1
20130150767 Tsyrulnykov et al. Jun 2013 A1
20130150811 Horgan Jun 2013 A1
20140207086 Stats et al. Jul 2014 A1
20150190622 Saab Jul 2015 A1
20150196704 Adler Jul 2015 A1
20150250933 Kerkhoffs et al. Sep 2015 A1
20150258322 Young et al. Sep 2015 A1
20150265280 Blatter et al. Sep 2015 A1
20150273201 Tallarida et al. Oct 2015 A1
20150290446 Wiley et al. Oct 2015 A1
20150306300 Phillips et al. Oct 2015 A1
20150327844 Hong et al. Nov 2015 A1
20160001055 Bourne et al. Jan 2016 A1
20190232035 Fedor et al. Aug 2019 A1
Foreign Referenced Citations (66)
Number Date Country
1261698 Sep 1989 CA
2318089 Jul 1999 CA
2551680 Jul 2005 CA
102271737 Dec 2011 CN
0229729 Jul 1987 EP
0366814 May 1990 EP
0 809 523 Dec 1997 EP
1047473 Nov 2000 EP
1056506 Dec 2000 EP
2948121 Nov 2017 EP
H05-506591 Sep 1993 JP
H07-148206 Jun 1995 JP
H08-501008 Feb 1996 JP
2008-531226 Aug 2008 JP
1991012838 Sep 1991 WO
1993005730 Apr 1993 WO
1994005246 Mar 1994 WO
9625196 Aug 1996 WO
1996029112 Sep 1996 WO
1997001370 Jan 1997 WO
1997006845 Feb 1997 WO
1998017337 Apr 1998 WO
1999034859 Jul 1999 WO
1999042166 Aug 1999 WO
2000033901 Jun 2000 WO
2000044424 Aug 2000 WO
2000053245 Sep 2000 WO
2001026713 Apr 2001 WO
0180926 Nov 2001 WO
2002038460 May 2002 WO
2002066595 Aug 2002 WO
2003066126 Aug 2003 WO
2004004800 Jan 2004 WO
2004071555 Aug 2004 WO
2004091434 Oct 2004 WO
2004093970 Nov 2004 WO
2005068009 Jul 2005 WO
2006064753 Jun 2006 WO
2006078915 Jul 2006 WO
2006096686 Sep 2006 WO
2006116438 Nov 2006 WO
2006130133 Dec 2006 WO
2006134100 Dec 2006 WO
2007079024 Jul 2007 WO
2007082003 Jul 2007 WO
2007087460 Aug 2007 WO
2007092210 Aug 2007 WO
2007094898 Aug 2007 WO
2007098771 Sep 2007 WO
2007109164 Sep 2007 WO
2007126645 Nov 2007 WO
2007136538 Nov 2007 WO
2008048361 Apr 2008 WO
2008063226 May 2008 WO
2008140901 Nov 2008 WO
2008157763 Dec 2008 WO
2009002839 Dec 2008 WO
2009012385 Jan 2009 WO
2009035582 Mar 2009 WO
2009046439 Apr 2009 WO
2009108669 Sep 2009 WO
2012064881 May 2012 WO
2014017986 Jan 2014 WO
2014116810 Jul 2014 WO
2015179862 Nov 2015 WO
2019200304 Oct 2019 WO
Non-Patent Literature Citations (23)
Entry
“Merge”. Merriam-Webster Dictionary. https://www.merriam-webster.com/dictionary/merge. Access May 13, 2021. (Year: 2021).
Canaud, B. et. al. “Dialock: a new vascular access device for extracorporeal renal replacement therapy. Preliminary clinical results”—Mar. 1999.
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jan. 20, 2016.
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated Jul. 19, 2016.
CN 201480005902.2 filed Jul. 23, 2015 Office Action dated May 12, 2017.
EP 14743846.9 filed Aug. 12, 2015 Extended European Search Report dated Oct. 10, 2016.
EP 14743846.9 filed Aug. 12, 2015 Intent to Grant dated Jun. 26, 2017.
Goldstein, D. J. et al. “Implantable Left Ventricular Assist Devices” (Nov. 19, 1998).
Moran, J. E. “Subcutaneous Vascular Access Devices” (Nov. 1, 2001).
PCT/US2014/012721 filed Jan. 23, 2014 International Search Report and Written Opinion dated Apr. 14, 2014.
Rosenblatt, M. et. al. “Efficacy and Safety Results with the LifeSite Hemodialysis Access System versus the Tesio-Cath Hemodialysis Catheter at 12 Months”—Mar. 2006.
Sandhu, J. Dialysis Ports: A New Totally Implantable Option for Hemodialysis Access—Jun. 2002.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Final Office Action dated May 25, 2017.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated May 4, 2016.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated Nov. 22, 2016.
JP 2015-555266 filed Jul. 22, 2015 Office Action dated May 2, 2018.
JP 2015-555266 filed Jul. 22, 2015 Office Action dated Oct. 12, 2017.
PCT/US2017/061179 filed Nov. 10, 2017 International Search Report and Written Opinion dated Jan. 22, 2018.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Final Office Action dated Jul. 2, 2018.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Non-Final Office Action dated Dec. 11, 2017.
U.S. Appl. No. 14/162,113, filed Jan. 23, 2014 Notice of Allowance dated Aug. 14, 2019.
U.S. Appl. No. 29/616,511, filed Sep. 6, 2017 Notice of Allowance dated Aug. 8, 2019.
U.S. Appl. No. 29/716,554, filed Dec. 10, 2019 Notice of Allowance dated Feb. 6, 2020.
Related Publications (1)
Number Date Country
20180078751 A1 Mar 2018 US
Provisional Applications (3)
Number Date Country
62552681 Aug 2017 US
62421131 Nov 2016 US
61755913 Jan 2013 US
Continuation in Parts (1)
Number Date Country
Parent 14162113 Jan 2014 US
Child 15809879 US